GLMD
NASDAQGalmed Pharmaceuticals Ltd.
News · 26 weeks46-25%
2026-03-012026-08-23
Mix2390d
- SEC Filings16(70%)
- Other7(30%)
Latest news
25 items- SECAmendment: SEC Form 6-K/A filed by Galmed Pharmaceuticals Ltd.6-K/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyThe prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.R
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer ModelsXtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue.Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately $8 billion and $6 billion globally in 2024 and 2025, respectively.The main composition of matter patents for enzalutamide (sold as Xtandi) expire in 2026 in Europe and 2027 in the United States (Patent US9126941 & Patent US8183274) with a U.S. price cut scheduled to begin in 2027.New data from a VCaP prostate cancer cell line that f
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion MarketAramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was developed demonstrating ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral administration.Aramchol's ODF is characterized by rapid buccal and sublingual absorption and reduced first-pass hepatic metabolism, designed to maximize drug exposure within the brain.Galmed believes that the development of a clinically characterized SCD1 inhibitor with a CNS-optimiz
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, AramcholGalmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle.Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.Aramchol's anti-fibrotic effects were demonstrated in the liver in a Phase 3 (open label part) MASH study as well as in human heart organoids and in-vivo lung and heart models.Traditional Aramchol formulation results in 80-90% accumulation in the liver and has limited effect on th
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 424B3 filed by Galmed Pharmaceuticals Ltd.424B3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of AcquisitionColospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ:GLMD) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate reimbursement in GermanyStrategic and Financial HighlightsRestructured Anti-Dilutive Financial Terms: To diminish the dilutive event on GLMD's existing shareholders, Galmed and Colospan agreed that in lieu of issuing $2.0 million in Galmed ordinary shares at closing, the cash payment shall be increased by $800K. The remaining balance has been structured as a transparent, risk-mitigated earnout capped at $2.0 million, commencing in Q3 2027. This single-digit percentage earnout on net sales reve
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form POS EX filed by Galmed Pharmaceuticals Ltd.POS EX - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 424B3 filed by Galmed Pharmaceuticals Ltd.424B3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion MarketTransaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerland.Upon closing, Colospan will become a wholly owned subsidiary of Galmed, repositioning it as a GI-focused medtech and biopharmaceutical platform. Transaction approved by both boards; expected to clo
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models.- In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) while preserving cardiac muscle integrity and metabolic function.REHOVOT, Israel and RAMAT-GAN, Israel, June 2, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, an
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mgResults from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling:Production of GMP clinical batch for Galmed's upcoming clinical trialsSolidification and prolongation of Aramchol's IP protectionPotential reduction in drug CoGs by ~50%Improvement in patients' convenience and compliance upon potential commercializationRAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001). The overall ob
GLMD FAQ
6 questionsWhat does Galmed Pharmaceuticals Ltd. do?
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino...Where does GLMD stock trade?
Galmed Pharmaceuticals Ltd. (GLMD) is listed on NASDAQ.What sector and industry is GLMD in?
Galmed Pharmaceuticals Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Galmed Pharmaceuticals Ltd. go public?
Galmed Pharmaceuticals Ltd. (GLMD) completed its IPO in 2014.What companies are similar to GLMD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GLMD side-by-side with any of them on Quantisnow.How can I track GLMD on Quantisnow?
Quantisnow aggregates Galmed Pharmaceuticals Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLMD to receive live email and push alerts on every new disclosure.